Takeda Pharmaceutical Co Ltd (TAK)
13.25
-0.12
(-0.90%)
USD |
NYSE |
May 10, 16:00
13.34
+0.09
(+0.68%)
After-Hours: 20:00
Takeda Pharmaceutical Enterprise Value: 70.46B for May 10, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 10, 2024 | 70.46B |
| May 09, 2024 | 70.84B |
| May 08, 2024 | 69.87B |
| May 07, 2024 | 70.56B |
| May 06, 2024 | 70.81B |
| May 03, 2024 | 70.84B |
| May 02, 2024 | 70.52B |
| May 01, 2024 | 70.27B |
| April 30, 2024 | 69.93B |
| April 29, 2024 | 70.21B |
| April 26, 2024 | 69.77B |
| April 25, 2024 | 69.90B |
| April 24, 2024 | 70.40B |
| April 23, 2024 | 70.87B |
| April 22, 2024 | 70.81B |
| April 19, 2024 | 70.43B |
| April 18, 2024 | 70.18B |
| April 17, 2024 | 70.15B |
| April 16, 2024 | 70.40B |
| April 15, 2024 | 70.24B |
| April 12, 2024 | 70.84B |
| April 11, 2024 | 71.50B |
| April 10, 2024 | 71.47B |
| April 09, 2024 | 71.72B |
| April 08, 2024 | 71.78B |
| Date | Value |
|---|---|
| April 05, 2024 | 71.62B |
| April 04, 2024 | 71.18B |
| April 03, 2024 | 71.34B |
| April 02, 2024 | 71.40B |
| April 01, 2024 | 71.78B |
| March 31, 2024 | 72.47B |
| March 28, 2024 | 74.41B |
| March 27, 2024 | 75.35B |
| March 26, 2024 | 75.98B |
| March 25, 2024 | 75.23B |
| March 22, 2024 | 76.04B |
| March 21, 2024 | 75.89B |
| March 20, 2024 | 76.48B |
| March 19, 2024 | 76.04B |
| March 18, 2024 | 76.51B |
| March 15, 2024 | 76.23B |
| March 14, 2024 | 75.82B |
| March 13, 2024 | 76.08B |
| March 12, 2024 | 75.92B |
| March 11, 2024 | 76.55B |
| March 08, 2024 | 77.17B |
| March 07, 2024 | 77.46B |
| March 06, 2024 | 76.92B |
| March 05, 2024 | 76.01B |
| March 04, 2024 | 76.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
65.66B
Minimum
Oct 19 2022
107.09B
Maximum
Nov 19 2019
85.04B
Average
80.44B
Median
Enterprise Value Benchmarks
| Astellas Pharma Inc | 21.58B |
| Nxera Pharma Co Ltd | 1.018B |
| PeptiDream Inc | 1.685B |
| Healios KK | 73.17M |
| AnGes Inc | 37.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.33M |
| Revenue (Quarterly) | 7.081B |
| Total Expenses (Quarterly) | 7.148B |
| EPS Diluted (Quarterly) | -0.0068 |
| Gross Profit Margin (Quarterly) | 63.60% |
| Profit Margin (Quarterly) | -0.29% |
| Earnings Yield | 2.43% |
| Operating Earnings Yield | 3.03% |
| Normalized Earnings Yield | 2.428 |